GlassScriptPhysician profile
Jenny S Walsh
NPI 1861835142
$2,378.21
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $516 · 2021: $1,396 · 2022: $448 · 2024: $18.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $282.04 | 2020-2022 | |
| Amgen INC. | $217.58 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $180.13 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.15 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.10 | 2020-2021 | |
| Abbvie INC. | $155.30 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $131.08 | 2020-2022 | |
| Pfizer INC. | $115.56 | 2020-2022 | |
| Novo Nordisk INC | $106.60 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $105.18 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $96.97 | 2020-2022 | |
| Lilly USA, LLC | $92.72 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $86.63 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $84.11 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $73.39 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $67.73 | 2020-2021 | |
| Kyowa Kirin, INC. | $53.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.02 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $20.86 | 2022 | |
| Exact Sciences Corporation | $18.57 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $17.88 | 2021 | |
| Celgene Corporation | $17.38 | 2021 | |
| Dexcom, INC. | $15.05 | 2021 | |
| Genentech USA, INC. | $13.18 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.51 | 2022 | |
| Allergan, INC. | $12.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.